Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20605272 | 0.87 | WDR5 (0.62) | WDR5 | |
| SCHEMBL29790014 | 0.85 | WDR5 (0.59) | WDR5 | |
| SCHEMBL20606478 | 0.85 | WDR5 (0.59) | WDR5 | |
| SCHEMBL20896855 | 0.85 | WDR5 (0.59) | WDR5 | |
| SCHEMBL20914836 | 0.82 | WDR5 (0.67) | WDR5 | |
| SCHEMBL20896294 | 0.76 | WDR5 (0.61) | WDR5 | |
| SCHEMBL20896291 | 0.76 | WDR5 (0.61) | WDR5 | |
| SCHEMBL20896556 | 0.74 | WDR5 (0.57) | WDR5 | |
| SCHEMBL20896611 | 0.74 | WDR5 (0.57) | WDR5 | |
| SCHEMBL29789992 | 0.74 | WDR5 (0.57) | WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174250-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-11174250-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20190119264-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20190119264-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-25 | — | — | US | disclosed |
| EP-3423437-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174250-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | WDR5 1/4885 |
| US-20190119264-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | WDR5 1/4885 |
| US-20160130256-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | WDR5 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.